Drug Trial Radar · NCT06844214
A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Jul 23, 2025
Primary completion
Feb 28, 2029
Study completion Apr 27, 2032
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Feb 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 10 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/Phase 2 open-label single arm, multicenter, and multinational study with SAR446268 for treatment of male and female participants 10 to 55 years old with non-congenital myotonic dystrophy (DM) type 1 (DM1). The purpose of this study is to evaluate the safety and efficacy of SAR446268 in knocking down dystrophia myotonica protein kinase (DMPK) messenger ribonucleic acid (mRNA) levels and improving neuromuscular function in DM1 participants receiving a single intravenous (IV) administration of SAR446268. The study consists of a dose escalation part (Part A) during which single ascending doses of SAR446268 will be evaluated in 3 distinct cohorts and an optional fourth dose cohort. Once a safe and effective dose is identified, additional participants will be treated in Part B, the dose expansion phase of the study. The study duration will be 112 weeks (approximately 2 years) for each participant in Parts A and B respectively and includes an optional pre-screening period, approximately 8-week screening phase and a 104-week follow-up period post-SAR446268 administration.
Conditions
- Myotonic Dystrophy
Interventions
SAR446268Biological
Pharmaceutical form: Solution for infusion; Route of administration: IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A and Part B: Incidence of treatment-emergent adverse events (TEAEs) following SAR446268 administrationTime frame: Baseline to Week 52
- Part B: Proportion of participants with at least 40% DMPK mRNA knockdown in muscle biopsy at Weeks 12 and 52 following SAR446268 administrationTime frame: Weeks 12 and 52
Locations
10 sites in 6 countries. Site status is shown where the registry gives one.
University of Florida, 2004 Mowry Road - Site Number: 8400005
Gainesville, Florida · Recruiting
University of South Florida - Neuromuscular Research, 13330 USF Laurel Drive - Site Number: 8400001
Tampa, Florida · Recruiting
Columbia University Medical Center - Neurological Institute, 710 W. 168th, 2nd floor, suite 204 - Site Number : 8400003
New York, New York · Recruiting
Penn Medicine: University of Pennsylvania Health System- Site Number : 8400009
Philadelphia, Pennsylvania · Recruiting
Virginia Commonwealth University Medical Center- Site Number : 8400006
Richmond, Virginia · Recruiting
Hospital Italiano de Buenos Aires, Juan Domingo Peron 4190 - Site Number: 0320001
Buenos Aires, Argentina · Recruiting
Investigational Site Number : 0360001
Brisbane, Queensland, Australia · Recruiting
The Montreal Neurological Institute and Hospital, 3801 rue University - Site Number: 1240001
Montreal, Quebec, Canada · Recruiting
Investigational Site Number : 3760002
Ramat Gan, Israel · Recruiting
Investigational Site Number : 8260002
Newcastle upon Tyne, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.